[{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"NXP900","moa":"||YES1\/Src-family kinase","graph1":"Oncology","graph2":"Preclinical","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"NXP900","moa":"||YES1\/Src-family kinase","graph1":"Oncology","graph2":"Preclinical","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NXP900","moa":"YES1\/Src-family kinase","graph1":"Oncology","graph2":"Preclinical","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NXP900","moa":"YES1\/Src-family kinase","graph1":"Oncology","graph2":"Phase I","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Nuvectis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Institute of Genetics and Cancer","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"NXP900","moa":"YES1\/Src-family kinase","graph1":"Oncology","graph2":"Preclinical","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Institute of Genetics and Cancer","highestDevelopmentStatusID":"4","companyTruncated":"Nuvectis Pharma \/ Institute of Genetics and Cancer"},{"orgOrder":0,"company":"Nuvectis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"NXP900","moa":"YES1\/Src-family kinase","graph1":"Oncology","graph2":"IND Enabling","graph3":"Nuvectis Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Nuvectis Pharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Nuvectis Pharma \/ Inapplicable"}]